Edwards Lifesciences had a trading volume of $507 million on February 6th, ranking 292nd among U.S. stocks on that day.

K-LinePoet · 2026-03-06T19:05:41+00:00

On February 6, 2026, healthcare equipment company Edwards Lifesciences (EW) had a trading volume of $507 million, ranking 292nd among U.S. stocks on that day. The trading volume decreased by 7.37% compared to yesterday, with a daily trading volume of 6.4762 million.Edwards Lifesciences (EW) rose 0.78% on February 6, 2026, closing at $78.71. The stock has fallen 3.26% over the past 5 trading days, down 3.26% for the entire February, and down 7.67% year-to-date. Over the past 52 weeks, it has increased by 10.87%.If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to companies listed for less than 1 month or fewer than 5 trading days).| Edwards Lifesciences (EW) | Trading Volume / USD | Change in Trading Volume from Yesterday | Trading Volume || --- | --- |

K-LinePoet

2026-03-06 19:05:41

On February 6, 2026, Edwards Lifesciences (EW), a healthcare equipment company, had a trading volume of $507 million, ranking 292nd among U.S. stocks that day. The trading volume decreased by 7.37% compared to the previous day, with a total of 6.4762 million shares traded.

Edwards Lifesciences (EW) closed at $78.71 on February 6, 2026, up 0.78%. Over the past five trading days, the stock has decreased by 3.26%. For the entire month of February, it has declined by 3.26%. Year-to-date, it is down 7.67%. Over the past 52 weeks, it has increased by 10.87%.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to companies listed for less than 1 month or fewer than 5 trading days).

Edwards Lifesciences (EW)	Trading Volume / USD	Change from Previous Day	Shares Traded
February 6, 2026	$507 million	-7.37%	6.4762 million
February 5, 2026	$547 million	+5.22%	6.9891 million
February 4, 2026	$520 million	+86.21%	6.4618 million
February 3, 2026	$279 million	-10.47%	3.3898 million
February 2, 2026	$312 million	+3.48%	3.7791 million

Edwards Lifesciences released its third-quarter fiscal 2025 report (cumulative) on November 5, 2025. From January 1 to September 30, 2025, revenue was $4.498 billion, a 10.96% increase year-over-year. Net profit was $978 million, down 74.16% year-over-year.

Edwards Lifesciences was founded on September 10, 1999, in Delaware. The company is a global leader in structural heart disease, critical care, and surgical monitoring. Driven by a passion to help patients, it collaborates with leading clinicians and researchers worldwide, investing in R&D to transform care for patients with structural heart disease or those requiring hemodynamic monitoring during surgery or critical care.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.